A German-American team of researchers has developed a compound that could affect latent herpes simplex virus (HSV) infections, reducing the risk of recurrence even after an infection had fully established itself in its neuronal reservoir.

Mindup, an Israeli digital health incubator, added Phenofast Ltd. to its portfolio this week, banking on the startup’s ability to resolve a critical, ongoing problem for hospitals and community physicians treating patients with urinary tract infections (UTIs). Phenofast hopes to bring clarity to antimicrobial susceptibility testing (AST) and relief to patients in record time.